Clinical Benefits and Considerations of Bisphosphonate Treatment in Metastatic Bone Disease

Fred Saad, Allan Lipton

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Patients with metastatic bone disease are at risk for developing skeletal-related events that can negatively influence quality of life, contributing to loss of autonomy and functional capabilities. Bisphosphonates have become an important component in the treatment of patients with bone metastases as they delay the onset and reduce the risk of skeletal-related events and also palliate or control bone pain in multiple cancer types, thus preserving quality of life. Zoledronic acid has proven efficacy and safety in patients with bone lesions from breast cancer, prostate cancer, lung cancer, and other solid tumors, as well as in patients with multiple myeloma. Current data suggest that early treatment with zoledronic acid (before the onset of bone pain) may provide additional clinical benefits and also positive effects on survival in subsets of patients who have elevated levels of N-telopeptide of type I collagen (NTX), a biochemical marker of bone resorption. Studies have shown that in patients with breast cancer, prostate cancer, lung cancer, or other solid tumors, normalization of elevated levels of NTX was observed in the majority of patients who received zoledronic acid. Furthermore, normalization of NTX values correlated with extended survival.

Original languageEnglish (US)
JournalSeminars in oncology
Volume34
Issue numberSUPPL. 4
DOIs
StatePublished - Jan 1 2007

Fingerprint

zoledronic acid
Bone Diseases
Diphosphonates
Lung Neoplasms
Prostatic Neoplasms
Bone and Bones
Therapeutics
Quality of Life
Breast Neoplasms
Pain
Neoplasms
Survival
Patient Safety
Bone Resorption
Collagen Type I
Multiple Myeloma
Biomarkers
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

@article{ca155cc7ae7a41179f62e9d53ca0c0ed,
title = "Clinical Benefits and Considerations of Bisphosphonate Treatment in Metastatic Bone Disease",
abstract = "Patients with metastatic bone disease are at risk for developing skeletal-related events that can negatively influence quality of life, contributing to loss of autonomy and functional capabilities. Bisphosphonates have become an important component in the treatment of patients with bone metastases as they delay the onset and reduce the risk of skeletal-related events and also palliate or control bone pain in multiple cancer types, thus preserving quality of life. Zoledronic acid has proven efficacy and safety in patients with bone lesions from breast cancer, prostate cancer, lung cancer, and other solid tumors, as well as in patients with multiple myeloma. Current data suggest that early treatment with zoledronic acid (before the onset of bone pain) may provide additional clinical benefits and also positive effects on survival in subsets of patients who have elevated levels of N-telopeptide of type I collagen (NTX), a biochemical marker of bone resorption. Studies have shown that in patients with breast cancer, prostate cancer, lung cancer, or other solid tumors, normalization of elevated levels of NTX was observed in the majority of patients who received zoledronic acid. Furthermore, normalization of NTX values correlated with extended survival.",
author = "Fred Saad and Allan Lipton",
year = "2007",
month = "1",
day = "1",
doi = "10.1053/j.seminoncol.2007.10.006",
language = "English (US)",
volume = "34",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 4",

}

Clinical Benefits and Considerations of Bisphosphonate Treatment in Metastatic Bone Disease. / Saad, Fred; Lipton, Allan.

In: Seminars in oncology, Vol. 34, No. SUPPL. 4, 01.01.2007.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical Benefits and Considerations of Bisphosphonate Treatment in Metastatic Bone Disease

AU - Saad, Fred

AU - Lipton, Allan

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Patients with metastatic bone disease are at risk for developing skeletal-related events that can negatively influence quality of life, contributing to loss of autonomy and functional capabilities. Bisphosphonates have become an important component in the treatment of patients with bone metastases as they delay the onset and reduce the risk of skeletal-related events and also palliate or control bone pain in multiple cancer types, thus preserving quality of life. Zoledronic acid has proven efficacy and safety in patients with bone lesions from breast cancer, prostate cancer, lung cancer, and other solid tumors, as well as in patients with multiple myeloma. Current data suggest that early treatment with zoledronic acid (before the onset of bone pain) may provide additional clinical benefits and also positive effects on survival in subsets of patients who have elevated levels of N-telopeptide of type I collagen (NTX), a biochemical marker of bone resorption. Studies have shown that in patients with breast cancer, prostate cancer, lung cancer, or other solid tumors, normalization of elevated levels of NTX was observed in the majority of patients who received zoledronic acid. Furthermore, normalization of NTX values correlated with extended survival.

AB - Patients with metastatic bone disease are at risk for developing skeletal-related events that can negatively influence quality of life, contributing to loss of autonomy and functional capabilities. Bisphosphonates have become an important component in the treatment of patients with bone metastases as they delay the onset and reduce the risk of skeletal-related events and also palliate or control bone pain in multiple cancer types, thus preserving quality of life. Zoledronic acid has proven efficacy and safety in patients with bone lesions from breast cancer, prostate cancer, lung cancer, and other solid tumors, as well as in patients with multiple myeloma. Current data suggest that early treatment with zoledronic acid (before the onset of bone pain) may provide additional clinical benefits and also positive effects on survival in subsets of patients who have elevated levels of N-telopeptide of type I collagen (NTX), a biochemical marker of bone resorption. Studies have shown that in patients with breast cancer, prostate cancer, lung cancer, or other solid tumors, normalization of elevated levels of NTX was observed in the majority of patients who received zoledronic acid. Furthermore, normalization of NTX values correlated with extended survival.

UR - http://www.scopus.com/inward/record.url?scp=36549061521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549061521&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2007.10.006

DO - 10.1053/j.seminoncol.2007.10.006

M3 - Article

C2 - 18068486

AN - SCOPUS:36549061521

VL - 34

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 4

ER -